Fortis Advisors’s Corcept Therapeutics CORT Stock Holding History

Fortis Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-15,028	Closed	-$179K	–	198
2020 Q1	$179K	Buy	+15,028	New	+$186K	0.12%	88

Other funds holding CORT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fortis Advisors's CORT Position: Q2 2020 in Review

Fortis Advisors sold out of Corcept Therapeutics (CORT) in Q2 2020, closing a stake of 15,028 shares — an estimated $179K sold.

Fortis Advisors first reported a position in CORT in Q1 2020 and held it in 1 quarter. The position peaked at $179K in Q1 2020. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2020.

Fortis Advisors reported no remaining Corcept Therapeutics position as of Q2 2020 after selling out during the quarter.
Fortis Advisors sold 15,028 Corcept Therapeutics shares in Q2 2020, an estimated $179K.
Fortis Advisors first reported a position in Corcept Therapeutics in Q1 2020 and held it in 1 quarter.
Fortis Advisors's Corcept Therapeutics position peaked at $179K in Q1 2020.
224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2020.

Based on Fortis Advisors's 13F filing for Q2 2020, filed 13 Aug 2020.